- Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU(®)-Multi-HIVB, in untreated HIV-1 infected subjectsEftyhia Vardas
Lancet Laboratories, Richmond, Johannesburg, South Africa
Vaccine 30:4046-54. 2012..We evaluated the safety, immunogenicity and clinical effect of a novel recombinant plasmid DNA therapeutic HIV-1 vaccine, GTU(®)-multi-HIVB, containing 6 different genes derived from an HIV-1 subtype B isolate...
- External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continentsEftyhia Vardas
Division of Medical Virology, University of Stellenbosch, South Africa and Lancet Laboratories, Johannesburg, South Africa
J Infect Dis 203:58-65. 2011..We examined the baseline prevalence of penile, scrotal, and perineal/perianal human papillomavirus (HPV) in heterosexual men (HM). We also evaluated baseline characteristics of HM to assess factors associated with prevalent HPV detection...